Stock EUROCINE VACCINES AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Eurocine Vaccines AB Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm
Other stock markets
- - Intraday chart for Eurocine Vaccines AB
28/02 Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
15/02 Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.
CI
Correction - Eurocine Vaccines discloses interim report for July - September 2023
AQ
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Eurocine Vaccines discloses interim report for Juli - September 2023
AQ
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
CI
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Eurocine Vaccines discloses interim report for July 2022 - March 2023
AQ
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
CI
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA
MT
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.
CI
Eurocine Vaccines discloses half-year report for July - December 2022
AQ
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
CI
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA
MT
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia
AQ
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia
CI
Outstanding results for Eurocine Vaccines' mRNA based HSV-2 candidate
AQ
Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
PU
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022
CI
Eurocine Vaccines Receives Patent Coverage In South Korea For Vaccine Candidate
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EUCI Stock
  4. Stock
  5. News Eurocine Vaccines AB